ES3038736T3 - Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma - Google Patents
Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphomaInfo
- Publication number
- ES3038736T3 ES3038736T3 ES19707683T ES19707683T ES3038736T3 ES 3038736 T3 ES3038736 T3 ES 3038736T3 ES 19707683 T ES19707683 T ES 19707683T ES 19707683 T ES19707683 T ES 19707683T ES 3038736 T3 ES3038736 T3 ES 3038736T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- diffuse large
- cell lymphoma
- hit
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2018018679 | 2018-02-20 | ||
| PCT/US2019/018472 WO2019164794A1 (en) | 2018-02-20 | 2019-02-19 | Methods of use for trisubstituted benzotriazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3038736T3 true ES3038736T3 (en) | 2025-10-14 |
Family
ID=61692059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19707683T Active ES3038736T3 (en) | 2018-02-20 | 2019-02-19 | Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11717512B2 (https=) |
| EP (1) | EP3755324B1 (https=) |
| JP (2) | JP7434185B2 (https=) |
| KR (1) | KR102861339B1 (https=) |
| CN (1) | CN111757731B (https=) |
| AU (1) | AU2019223906B2 (https=) |
| BR (1) | BR112020016929A8 (https=) |
| CA (1) | CA3091792A1 (https=) |
| ES (1) | ES3038736T3 (https=) |
| MA (1) | MA51897A (https=) |
| MX (1) | MX2020008678A (https=) |
| TW (1) | TWI818954B (https=) |
| WO (1) | WO2019164794A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA48459B1 (fr) * | 2017-04-24 | 2021-09-30 | Aurigene Discovery Tech Ltd | Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| KR102861339B1 (ko) | 2018-02-20 | 2025-09-19 | 르 라보레또레 쎄르비에르 | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| PE20212197A1 (es) * | 2018-12-21 | 2021-11-16 | Les Laboratoires Servier Sas | Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo |
| CN111662872A (zh) * | 2020-05-06 | 2020-09-15 | 西南医科大学附属医院 | 一种急性t淋巴细胞白血病阿糖胞苷耐药细胞株构建方法 |
| CA3184024A1 (en) * | 2020-06-24 | 2021-12-30 | Les Laboratoires Servier | Use of a dhodh inhibitor compound in combination cancer therapy |
| WO2021262874A1 (en) | 2020-06-24 | 2021-12-30 | Servier Pharmaceuticals , Llc | Use of a dhodh inhibitor compound in combination cancer therapy |
| KR20230078997A (ko) * | 2020-08-27 | 2023-06-05 | 르 라보레또레 쎄르비에르 | 병용 암 요법에서의 dhodh 저해제 화합물의 용도 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996035419A1 (en) | 1995-05-10 | 1996-11-14 | Pfizer Inc. | Combination of methotrexate and tenidap for the treatment of rheumatoid arthritis |
| US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| JP2003510352A (ja) | 1999-10-01 | 2003-03-18 | インスティチュート オブ モレキュラー アンド セル バイオロジー | ウイルス媒介性疾病の治療用化合物 |
| MXPA04000224A (es) | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
| PL382308A1 (pl) * | 2004-08-25 | 2007-08-20 | Targegen, Inc. | Związki heterocykliczne i sposoby stosowania |
| ATE474833T1 (de) | 2004-09-22 | 2010-08-15 | Janssen Pharmaceutica Nv | Inhibitoren der wechselwirkung zwischen mdm2 und p53 |
| JP2007015952A (ja) | 2005-07-06 | 2007-01-25 | Shionogi & Co Ltd | ナフタレン誘導体 |
| DE102005049953A1 (de) | 2005-10-19 | 2007-04-26 | Sanofi-Aventis Deutschland Gmbh | Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| EP2066319B1 (en) | 2006-09-08 | 2012-02-01 | F. Hoffmann-La Roche AG | Benzotriazole kinase modulators |
| EP2387568A1 (en) | 2009-01-19 | 2011-11-23 | NeuroSearch A/S | Novel benzotriazole derivatives useful for the treatment of cns disorders |
| EP2230232A1 (en) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
| EP2228367A1 (en) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| US9316632B2 (en) | 2009-03-17 | 2016-04-19 | Marshall University Research Corporation | Methods of screening chemotherapeutic agents and treating cancer |
| WO2010115736A2 (en) | 2009-04-02 | 2010-10-14 | Merck Serono S.A. | Dihydroorotate dehydrogenase inhibitors |
| JP5967827B2 (ja) | 2009-12-09 | 2016-08-10 | アジオス ファーマシューティカルズ， インコーポレイテッド | Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物 |
| US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| CN103476770B (zh) | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
| WO2013049112A1 (en) | 2011-09-27 | 2013-04-04 | Emory University | Detection of biomarkers using magnetic resonance |
| CN103965133B (zh) | 2013-01-31 | 2018-11-30 | 华东理工大学 | 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途 |
| HRP20181908T1 (hr) | 2013-02-25 | 2019-01-11 | Aurigene Discovery Technologies Limited | Derivati trosupstituiranog benzotriazola kao inhibitori dihidroorotat oksigenaze |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| PL3139914T3 (pl) | 2014-05-08 | 2023-11-27 | Kiora Pharmaceuticals Gmbh | Związki stosowane w leczeniu chorób i schorzeń okulistycznych |
| WO2017037022A1 (en) * | 2015-09-01 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Compounds and methods useful for treating or preventing hematological cancers |
| EP3397625A4 (en) | 2015-12-30 | 2019-12-25 | Agios Pharmaceuticals, Inc. | TREATMENT OF TUMORS WITH MUTANT ISOCITRATE DEHYDROGENASE |
| JOP20190094A1 (ar) | 2016-10-27 | 2019-04-25 | Broad Inst Inc | مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) |
| WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| US11311548B2 (en) | 2017-03-02 | 2022-04-26 | Aslan Pharmaceuticals Pte. Ltd. | Cancer therapy |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| MA48459B1 (fr) | 2017-04-24 | 2021-09-30 | Aurigene Discovery Tech Ltd | Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase |
| WO2019012030A1 (en) | 2017-07-13 | 2019-01-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER |
| KR102861339B1 (ko) * | 2018-02-20 | 2025-09-19 | 르 라보레또레 쎄르비에르 | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| JP7126556B2 (ja) | 2018-09-28 | 2022-08-26 | 富士フイルム株式会社 | シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤 |
| JP7608336B2 (ja) | 2018-11-30 | 2025-01-06 | フォンダッツィオーネ・セントロ・サン・ラッファエーレ | 中枢神経系原発リンパ腫の併用治療 |
| PE20212197A1 (es) | 2018-12-21 | 2021-11-16 | Les Laboratoires Servier Sas | Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo |
| WO2021062157A1 (en) | 2019-09-27 | 2021-04-01 | The Rockefeller University | Compositions and methods for treating metastatic gastrointestinal cancer |
| WO2021262874A1 (en) | 2020-06-24 | 2021-12-30 | Servier Pharmaceuticals , Llc | Use of a dhodh inhibitor compound in combination cancer therapy |
| CA3184024A1 (en) | 2020-06-24 | 2021-12-30 | Les Laboratoires Servier | Use of a dhodh inhibitor compound in combination cancer therapy |
| KR20230078997A (ko) | 2020-08-27 | 2023-06-05 | 르 라보레또레 쎄르비에르 | 병용 암 요법에서의 dhodh 저해제 화합물의 용도 |
-
2019
- 2019-02-19 KR KR1020207024137A patent/KR102861339B1/ko active Active
- 2019-02-19 AU AU2019223906A patent/AU2019223906B2/en active Active
- 2019-02-19 EP EP19707683.9A patent/EP3755324B1/en active Active
- 2019-02-19 BR BR112020016929A patent/BR112020016929A8/pt unknown
- 2019-02-19 MA MA051897A patent/MA51897A/fr unknown
- 2019-02-19 WO PCT/US2019/018472 patent/WO2019164794A1/en not_active Ceased
- 2019-02-19 US US16/971,199 patent/US11717512B2/en active Active
- 2019-02-19 CA CA3091792A patent/CA3091792A1/en active Pending
- 2019-02-19 TW TW108105398A patent/TWI818954B/zh active
- 2019-02-19 ES ES19707683T patent/ES3038736T3/es active Active
- 2019-02-19 MX MX2020008678A patent/MX2020008678A/es unknown
- 2019-02-19 CN CN201980014469.1A patent/CN111757731B/zh active Active
- 2019-02-19 JP JP2020566525A patent/JP7434185B2/ja active Active
-
2023
- 2023-05-29 JP JP2023087801A patent/JP2023109974A/ja active Pending
- 2023-06-09 US US18/207,887 patent/US12290508B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020016929A8 (pt) | 2022-06-28 |
| TWI818954B (zh) | 2023-10-21 |
| CN111757731B (zh) | 2024-06-25 |
| KR20200123137A (ko) | 2020-10-28 |
| KR102861339B1 (ko) | 2025-09-19 |
| MA51897A (fr) | 2020-12-30 |
| AU2019223906A1 (en) | 2020-09-10 |
| JP2023109974A (ja) | 2023-08-08 |
| US20240148697A1 (en) | 2024-05-09 |
| US11717512B2 (en) | 2023-08-08 |
| US20210113531A1 (en) | 2021-04-22 |
| AU2019223906B2 (en) | 2024-11-21 |
| JP2021514395A (ja) | 2021-06-10 |
| US12290508B2 (en) | 2025-05-06 |
| CN111757731A (zh) | 2020-10-09 |
| EP3755324B1 (en) | 2025-07-30 |
| BR112020016929A2 (pt) | 2020-12-15 |
| CA3091792A1 (en) | 2019-08-29 |
| WO2019164794A1 (en) | 2019-08-29 |
| EP3755324A1 (en) | 2020-12-30 |
| MX2020008678A (es) | 2020-09-25 |
| TW201938543A (zh) | 2019-10-01 |
| EP3755324C0 (en) | 2025-07-30 |
| JP7434185B2 (ja) | 2024-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3038736T3 (en) | Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma | |
| AU2014372166B2 (en) | Pharmaceutical combinations | |
| AU2011302344B2 (en) | HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients | |
| ES2823756T3 (es) | Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR | |
| JP7577672B2 (ja) | Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物 | |
| CN112807434B (zh) | Perk抑制剂在制备肝癌药物的增效剂中的应用 | |
| RU2657783C2 (ru) | Комбинированная терапия с использованием азабициклосоединения для ракового заболевания | |
| TWI824010B (zh) | 治療血癌之組合療法 | |
| EP2043633B1 (en) | Thiadiazolidinone derivatives for treating cancer | |
| TW202329969A (zh) | 用於治療急性髓系白血病的ＦＬＴ３抑制劑和Ｂｃｌ－３抑制劑的治療有效組合 | |
| CN113490497A (zh) | 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物 | |
| EP2999465A1 (en) | Specific cancer treatment regimens with ganetespib | |
| WO2025157286A1 (zh) | 包含prmt5抑制剂和mat2a抑制剂的药物组合物 | |
| WO2025157288A1 (zh) | 包含prmt5抑制剂和cdk4/6抑制剂的药物组合物 | |
| CN112121052B (zh) | 丙烯酰基苯并氮杂䓬类化合物在制备防治血液肿瘤药物中的用途 | |
| HK40043674A (en) | Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma | |
| HK40043674B (en) | Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma | |
| CN116546986A (zh) | Alk-5抑制剂及其用途 | |
| WO2025070603A1 (ja) | 血液がんの新規併用療法 | |
| HK40066212A (en) | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | |
| Igarashi et al. | Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant | |
| HK1233936A1 (en) | Combinations for treating cancers |